Boryung Corporation engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. It offers prescription drugs for hypertension, dyslipidemia, and diabetes drugs. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is headquartered in Seoul, South Korea.
Research context
Boryung Pharmaceutical Co., Ltd appears in PyInvesting’s Korea Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Boryung Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 18.0% above its 200 day moving average.
From a valuation standpoint, the stock is 79.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.8.
Boryung Pharmaceutical Co., Ltd's total revenue sank by 0.4% to $138B since the same quarter in the previous year.
Its net income has dropped by 16.6% to $4B since the same quarter in the previous year.
Finally, its free cash flow fell by 60.1% to $-7B since the same quarter in the previous year.
Based on the above factors, Boryung Pharmaceutical Co., Ltd gets an overall score of 2/5.